MDL | - |
---|---|
Molecular Weight | 523.95 |
Molecular Formula | C20H15ClFN5O5S2 |
SMILES | O=S(C1=CC=C(Cl)S1)(NC(NC2=CC=C(N3C(NC4=C(C=C(F)C(NC)=C4)C3=O)=O)C=C2)=O)=O |
Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y 12 antagonist ( IC 50 =20 nM). It is orally and intravenously available and has potent antiplatelet effects [1] .
IC50: 20 nM (P2Y 12 ) [2]
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00751231 | Portola Pharmaceuticals |
Percutaneous Coronary Intervention
|
December 2008 | Phase 2 |
NCT00984113 | Portola Pharmaceuticals|Novartis |
Renal Impairment
|
September 2009 | Phase 1 |
NCT00546260 | Portola Pharmaceuticals |
Myocardial Infarction
|
November 2007 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 62.5 mg/mL ( 119.29 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.9086 mL | 9.5429 mL | 19.0858 mL |
5 mM | 0.3817 mL | 1.9086 mL | 3.8172 mL |
10 mM | 0.1909 mL | 0.9543 mL | 1.9086 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.97 mM); Clear solution